|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-6-5
|
|
pubmed:abstractText |
Oxaliplatin, a platinum compound, has been commonly used around the world for treating advanced colorectal cancer. The generally recommended dose and schedule of oxaliplatin monotherapy is 130 mg/m(2) every 3 weeks. This trial was conducted to evaluate the safety and pharmacokinetics of oxaliplatin monotherapy in Japanese patients with solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0368-2811
|
|
pubmed:author |
pubmed-author:BokuNarikazuN,
pubmed-author:GotohMasahiroM,
pubmed-author:MatsumuraYasuhiroY,
pubmed-author:MuroKeiK,
pubmed-author:MutohManabuM,
pubmed-author:NagashimaFumioF,
pubmed-author:OhtsuAtsushiA,
pubmed-author:SanoYasushiY,
pubmed-author:ShiraoKuniakiK,
pubmed-author:TanigawaraYusukeY,
pubmed-author:YamadaYasuhideY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
295-300
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16702162-Adult,
pubmed-meshheading:16702162-Anorexia,
pubmed-meshheading:16702162-Antineoplastic Agents,
pubmed-meshheading:16702162-Colorectal Neoplasms,
pubmed-meshheading:16702162-Dose-Response Relationship, Drug,
pubmed-meshheading:16702162-Drug Administration Schedule,
pubmed-meshheading:16702162-Female,
pubmed-meshheading:16702162-Humans,
pubmed-meshheading:16702162-Male,
pubmed-meshheading:16702162-Maximum Tolerated Dose,
pubmed-meshheading:16702162-Middle Aged,
pubmed-meshheading:16702162-Organoplatinum Compounds,
pubmed-meshheading:16702162-Peripheral Nervous System Diseases,
pubmed-meshheading:16702162-Platinum
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
|
|
pubmed:affiliation |
Gastrointestinal Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan. kshirao@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
